Efficacy of entecavir versus tenofovir in preventing hepatocellular carcinoma in patients with chronic hepatitis B with maintained virologic response
暂无分享,去创建一个
D. Sinn | W. Kang | M. Choi | K. Koh | S. Paik | G. Gwak | Jung-Hwan Yoon | Y. Kim | Jeong‐Hoon Lee | Heejoon Jang | Kyung-Ah Kim | Jieun Na | Seon Yeong Baek | Young-Han Paik | Joon Hyeok Lee | J. Yoon | Jung‐Hwan Yoon
[1] Y. Lim,et al. Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[2] Siddharth Singh,et al. Comparative Effectiveness of Entecavir Versus Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: A Systematic Review and Meta‐Analysis , 2020, Hepatology.
[3] B. Carr,et al. Inflammatory Mechanisms of HCC Development , 2020, Cancers.
[4] Wukui Cao,et al. Outcomes of Long-term Treatment of Chronic HBV Infection With Entecavir or Other Agents From a Randomized Trial in 24 Countries. , 2020, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[5] H. Vahaboğlu,et al. Tenofovir for the Prevention of HCC in Patients With Cirrhosis. , 2019, The American journal of gastroenterology.
[6] M. Yuen,et al. A large real‐world cohort study examining the effects of long‐term entecavir on hepatocellular carcinoma and HBsAg seroclearance , 2019, Journal of viral hepatitis.
[7] J. Sutinen,et al. Switching from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Significantly Worsens the Lipid Profile in a Real-World Setting. , 2019, AIDS patient care and STDs.
[8] J. Jang,et al. Comparison of tenofovir and entecavir on the risk of hepatocellular carcinoma and mortality in treatment-naïve patients with chronic hepatitis B in Korea: a large-scale, propensity score analysis , 2019, Gut.
[9] Rui Huang,et al. Tenofovir Versus Entecavir for Hepatocellular Carcinoma Prevention in an International Consortium of Chronic Hepatitis B. , 2019, The American journal of gastroenterology.
[10] Y. Tse,et al. Tenofovir is Associated With Lower Risk of Hepatocellular Carcinoma Than Entecavir in Patients With Chronic HBV Infection in China. , 2019, Gastroenterology.
[11] M. N. Kim,et al. A multi-center study of entecavir vs. tenofovir on prognosis of treatment-naïve chronic hepatitis B in the Republic of Korea. , 2019, Journal of hepatology.
[12] KASL clinical practice guidelines for management of chronic hepatitis B , 2019, Clinical and molecular hepatology.
[13] S. Ahn,et al. Comparison between chronic hepatitis B patients with untreated immune-tolerant phase vs. those with virological response by antivirals , 2019, Scientific Reports.
[14] Hyo Jeong Kim,et al. Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B: A Korean Nationwide Cohort Study , 2019, JAMA oncology.
[15] S. Alavian,et al. Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study. , 2018, The lancet. Gastroenterology & hepatology.
[16] S. Kottilil,et al. Chronic Hepatitis B Infection: A Review , 2018, JAMA.
[17] Y. Kim,et al. Current status and strategies for hepatitis B control in Korea , 2017, Clinical and molecular hepatology.
[18] D. Sinn,et al. Low‐level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment , 2017, Hepatology.
[19] J. Park,et al. Comparison of the long-term efficacy between entecavir and tenofovir in treatment- naïve chronic hepatitis B patients , 2017, BMC Gastroenterology.
[20] J. R. Rebello Pinho,et al. High Prevalence of ITPA Alleles Associated with Ribavirin-Induced Hemolytic Anemia Among Mexican Population. , 2017, Annals of hepatology.
[21] T. Tseng,et al. Four‐year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients , 2016, Liver international : official journal of the International Association for the Study of the Liver.
[22] D. Sinn,et al. Long-term real-world entecavir therapy in treatment-naïve hepatitis B patients: base-line hepatitis B virus DNA and hepatitis B surface antigen levels predict virologic response , 2016, The Korean journal of internal medicine.
[23] M. Buti,et al. Altered Underlying Renal Tubular Function in Patients With Chronic Hepatitis B Receiving Nucleos(t)ide Analogs in a Real-World Setting: The MENTE Study , 2016, Journal of clinical gastroenterology.
[24] T. Therneau,et al. Impact of long‐term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B , 2015, Cancer.
[25] Korea,et al. 2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma , 2015, Gut and liver.
[26] R. Idilman,et al. Long‐term entecavir or tenofovir disoproxil fumarate therapy in treatment‐naïve chronic hepatitis B patients in the real‐world setting , 2015, Journal of viral hepatitis.
[27] R. Paredes,et al. The lipid-lowering effect of tenofovir/emtricitabine: a randomized, crossover, double-blind, placebo-controlled trial. , 2015, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.
[28] Jaw-Town Lin,et al. Association of nucleos(t)ide analogue therapy with reduced risk of hepatocellular carcinoma in patients with chronic hepatitis B: a nationwide cohort study. , 2014, Gastroenterology.
[29] V. Wong,et al. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis , 2013, Hepatology.
[30] Yoshiyuki Suzuki,et al. Long‐term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection , 2013, Hepatology.
[31] Chang Duck Kim,et al. Prognosis of hepatitis B‐related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents , 2012, Journal of gastroenterology and hepatology.
[32] H. Yim,et al. KASL Clinical Practice Guidelines: Management of chronic hepatitis B , 2012, Clinical and molecular hepatology.
[33] B. Bell,et al. The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. , 2006, Journal of hepatology.
[34] Chien-Jen Chen,et al. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. , 2006, Gastroenterology.
[35] Guan-Tarn Huang,et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. , 2006, JAMA.
[36] C. W. Kim,et al. Hepatitis B Virus Genotype C Prevails Among Chronic Carriers of the Virus in Korea , 2005, Journal of Korean medical science.
[37] G. Práctica,et al. European Association for the Study of the Liver , 1971 .
[38] S. Alavian,et al. Combination of Ledipasvir and Sofosbuvir for Treatment of Hepatitis C Virus Genotype 1 Infection: Systematic Review and Meta-Analysis. , 2017, Annals of hepatology.
[39] T. Therneau,et al. Cirrhosis is present in most patients with hepatitis B and hepatocellular carcinoma. , 2011, Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association.
[40] [Practice guidelines for management of hepatocellular carcinoma 2009]. , 2009, The Korean journal of hepatology.
[41] P. Loehrer,et al. Risk of Hepatocellular Carcinoma Across a Biological Gradient of Serum Hepatitis B Virus DNA Level , 2007 .
[42] A. B. Sukhomlinov,et al. [Liver cirrhosis]. , 1989, Fel'dsher i akusherka.